Therefore, expect impact to the sectors mentioned in the original post starting October 2026 and progressively snowballing
While the clinical impact of GLP-1s on approved indications (e.g., obesity, diabetes, cardiovascular risk) and adjacent indications is being studied extensively in clinical trials, there is limited scientific literature on GLP-1 use, efficacy or persistence outside of clinical trial settings
supplemented different doses of LC (100 and 200 mg/kg diet) with vitamin C (1 g/kg diet) for 3 weeks and noted the reproductive performance of Golden Montahza laying hens, and reported increased egg production rate (2.1 and 2.7%) and egg quality [87]
In seeking to identify existing drugs with anti-fibrotic potential that could be repurposed, incretin receptor agonists, namely the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, are emerging as candidates
Lipid and cardiovascular markers Berberine has well-documented effects on lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides, as well as modest increases in HDL